[Preprint]. 2023 Sep 13:2023.05.15.23289680. Originally published 2023 May 16. [Version 2] doi: 10.1101/2023.05.15.23289680

Table 4:

All-grade and severe immune checkpoint inhibitor-mediated colitis (IMC) as predictors of progression-free survival (PFS) and overall survival (OS) in the entire GeRI cohort, using Cox proportional hazards models with 90-day landmark

IMC	PFS			OS

	HR	95% CI	P value	HR	95% CI	P value

All-grade	0.80	0.55–1.17	0.26	0.40	0.24–0.66	3×10⁻⁰⁴
Severe	0.61	0.34–1.09	0.09	0.23	0.09–0.55	9×10⁻⁰⁴

All models are adjusted for age at diagnosis, sex, histology, type of therapy, recruiting site, and 5 principal components. IMC: Immune checkpoint inhibitor-mediated colitis, PFS: Progression free survival, OS: Overall survival, HR: Hazards ratio, CI: Confidence interval